Lenalidomide: Patient management strategies

Seminars in Hematology

Volumn 42, Issue SUPPL. 4, 2005, Pages

  Hussein, Mohamad A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; AMOXICILLIN; ANTHRACYCLINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; DEXAMETHASONE; DOXORUBICIN; LAXATIVE; LENALIDOMIDE; LIVER ENZYME; LOW MOLECULAR WEIGHT HEPARIN; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FAMILIAL AMYLOID POLYNEUROPATHY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HERPES SIMPLEX; HUMAN; HYPERCOAGULABILITY; INFECTION; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MACULOPAPULAR RASH; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; THROMBOCYTOPATHY; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMANS; MULTIPLE MYELOMA; THALIDOMIDE;

EID: 28844496656     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2005.10.003     Document Type: Conference Paper

References (16)

1. S. Singhal, J. Mehta, R. Desikan Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
2. B. Barlogie, M. Zangari, T. Spencer Thalidomide in the management of multiple myeloma Semin Hematol 38 2001 250 259
3. R.A. Kyle, S.V. Rajkumar Therapeutic application of thalidomide in multiple myeloma Semin Oncol 28 2001 583 587
4. S.V. Rajkumar, A. Dispenzieri, R. Fonseca Thalidomide for previously untreated indolent or smoldering multiple myeloma Leukemia 15 2001 1274 1276
5. S.V. Rajkumar, S. Hayman, M.A. Gertz Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma J Clin Oncol 20 2002 4319 4323
6. I.M. Ghobrial, S.V. Rajkumar Management of thalidomide toxicity J Support Oncol 1 2003 194 205
7. Weber D: Two phase III randomized, double-blind, placebo-controlled trials of lenalidomide-dexamethasone vs. dexamethasone for refractory or relapsed multiple myeloma. Presented at a special session titled: IMiDs - Results of Phase III Studies in Relapsed/Refractory Myeloma. www.ASCO.org [Virtual Meeting], accessed on June 22, 2005.
8. M.A. Hussein Modification to therapy for multiple myeloma Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide Oncologist 8 suppl 3 2003 39 45
9. M.A. Hussein, P. Elson, E.A. Tsoe Doxil (D), vincristine (V), decadron (d) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM) Blood 100 2002 403a (abstr)
10. R.A. Kyle, S.V. Rajkumar Multiple myeloma N Engl J Med 351 2004 1860 1873
11. M.A. Hussein New treatment strategies for multiple myeloma Semin Hematol 41 2004 2 8
12. G. Srkalovic, M.G. Cameron, L. Rybicki Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease Cancer 101 2004 558 566
13. S.V. Rajkumar, S.R. Hayman, M.Q. Lacy Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma Blood 2005
14. R. Baz, L. Li, K. Kottke-Marchant The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma Mayo Clin Proc 2005 (in press)
15. SWOG: Phase III randomized study of dexamethasone with or without CC-5013 in patients with newly diagnosed multiple myeloma. http://multiplemyeloma.org/ clinical_trials/ctm/4.04.144.html, accessed June 28, 2005.
16. P.G. Richardson, S. Jagannath, R. Schlossman A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (dex) for the treatment of relapsed or refractory multiple myeloma (MM) Blood 102 2003 235A (abstr 235A)